IFNA2 and systemic lupus erythematosus: While IFN‐β is an established therapy in relapsing MS and the interferon‐alpha/beta receptor (IFNAR) signaling on myeloid cells limits autoimmunity in the CNS [4], IFN‐α drives pathogenesis in SLE.